Respiratory Medicine and Research最新文献

英文中文

Interstitial lung disease mortality rates and disparities across U.S. states 美国各州间质性肺病死亡率和差异

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2026-01-16 DOI: 10.1016/j.resmer.2026.101252

Eva Ma , Pengyi Zhu , Niranjan Jeganathan

引用次数: 0

Hit-hard vs step-up therapies in COPD: the Goldilocks dilemma 慢性阻塞性肺病的重击vs强化治疗：金发姑娘困境

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2026-01-14 DOI: 10.1016/j.resmer.2026.101246

Belen Muñoz-Sanchez , José Luis Lopez-Campos , Esther Quintana-Gallego

引用次数: 0

Vibrating mesh nebulization increases tidal volume relative to jet nebulization during NIV in COPD exacerbation 振动网雾化增加潮汐容积相对于喷射雾化在NIV期间COPD加重

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2026-01-12 DOI: 10.1016/j.resmer.2026.101248

César Cinesi-Gomez, María Garcia-Palacios, Lorena Bernabe-Vera, Mabel Coromoto Suarez-Pineda, Elisa Serrano-Carrasco, Jose Andres Sanchez-Nicolas

Background and importance

Noninvasive ventilation (NIV) is the first-line treatment for acute exacerbations of chronic obstructive pulmonary disease (COPD) with hypercapnic respiratory failure (HRF). Bronchodilator therapy is essential during NIV, but real-world clinical comparisons of nebulization devices in this acute setting remain limited.

Objective

To compare the clinical efficacy of vibrating mesh nebulizers (VMN) versus jet nebulizers (JN) in COPD patients undergoing NIV, using changes in tidal volume (VT) as the primary outcome.

Design, settings and participants

A longitudinal observational study was performed in the ventilatory unit of the emergency department of a tertiary hospital. Patients requiring NIV for HRF were allocated to two cohorts: VMN (October 2023–March 2024) and JN (January 2015–May 2017). Ventilatory parameters, including VT, were recorded at baseline, 15 minutes, 1 hour, and 3 hours. The primary outcome was the percentage change in VT (ΔVT) from baseline.

Main results

Eighty-four patients were analyzed (VMN: n=41; JN: n=43). Baseline characteristics were comparable between groups. The VMN cohort exhibited a significantly greater increase in VT at 1 hour and 3 hours (p<0.05) compared with the JN cohort. ΔVT mirrored these findings. No significant correlation was observed between VT and pressure support levels.

Conclusion

In this real-world ED study of COPD patients treated with continuous NIV, VMN was associated with a greater early increase in VT than JN, consistent with more effective bronchodilator delivery. Given the historical, non-randomized design across different time periods and ventilators, and the use of VT as an indirect endpoint, these findings should be interpreted as hypothesis-generating but provide a clinically relevant starting point supporting preferential VMN use in acute practice.

背景和重要性无创通气（NIV）是慢性阻塞性肺疾病（COPD）急性加重伴高碳酸血症性呼吸衰竭（HRF）的一线治疗方法。在无创通气期间，支气管扩张剂治疗是必不可少的，但在这种急性情况下，雾化装置的实际临床比较仍然有限。目的以潮气量（VT）变化为主要观察指标，比较振动网状雾化器（VMN）与喷射雾化器（JN）治疗慢性阻塞性肺疾病（COPD）的临床疗效。设计、环境和参与者：在一家三级医院急诊科的通气科进行了一项纵向观察研究。需要NIV治疗HRF的患者被分配到两个队列：VMN（2023年10月- 2024年3月）和JN（2015年1月- 2017年5月）。在基线、15分钟、1小时和3小时记录包括VT在内的通气参数。主要结局是VT从基线的百分比变化（ΔVT）。主要结果共分析84例患者（VMN: n=41; JN: n=43）。各组间基线特征具有可比性。与JN组相比，VMN组在1小时和3小时的VT显著增加（p < 0.05）。ΔVT反映了这些发现。VT与压力支持水平无显著相关性。结论：在持续NIV治疗的COPD患者的现实ED研究中，VMN与早期VT增加相关，而不是JN，这与更有效的支气管扩张剂输送一致。考虑到历史上不同时期和不同呼吸机的非随机设计，以及使用VT作为间接终点，这些发现应该被解释为假设产生，但提供了一个临床相关的起点，支持在急性实践中优先使用VMN。

{"title":"Vibrating mesh nebulization increases tidal volume relative to jet nebulization during NIV in COPD exacerbation","authors":"César Cinesi-Gomez, María Garcia-Palacios, Lorena Bernabe-Vera, Mabel Coromoto Suarez-Pineda, Elisa Serrano-Carrasco, Jose Andres Sanchez-Nicolas","doi":"10.1016/j.resmer.2026.101248","DOIUrl":"10.1016/j.resmer.2026.101248","url":null,"abstract":"<div><h3>Background and importance</h3><div>Noninvasive ventilation (NIV) is the first-line treatment for acute exacerbations of chronic obstructive pulmonary disease (COPD) with hypercapnic respiratory failure (HRF). Bronchodilator therapy is essential during NIV, but real-world clinical comparisons of nebulization devices in this acute setting remain limited.</div></div><div><h3>Objective</h3><div>To compare the clinical efficacy of vibrating mesh nebulizers (VMN) versus jet nebulizers (JN) in COPD patients undergoing NIV, using changes in tidal volume (VT) as the primary outcome.</div></div><div><h3>Design, settings and participants</h3><div>A longitudinal observational study was performed in the ventilatory unit of the emergency department of a tertiary hospital. Patients requiring NIV for HRF were allocated to two cohorts: VMN (October 2023–March 2024) and JN (January 2015–May 2017). Ventilatory parameters, including VT, were recorded at baseline, 15 minutes, 1 hour, and 3 hours. The primary outcome was the percentage change in VT (ΔVT) from baseline.</div></div><div><h3>Main results</h3><div>Eighty-four patients were analyzed (VMN: n=41; JN: n=43). Baseline characteristics were comparable between groups. The VMN cohort exhibited a significantly greater increase in VT at 1 hour and 3 hours (p<0.05) compared with the JN cohort. ΔVT mirrored these findings. No significant correlation was observed between VT and pressure support levels.</div></div><div><h3>Conclusion</h3><div>In this real-world ED study of COPD patients treated with continuous NIV, VMN was associated with a greater early increase in VT than JN, consistent with more effective bronchodilator delivery. Given the historical, non-randomized design across different time periods and ventilators, and the use of VT as an indirect endpoint, these findings should be interpreted as hypothesis-generating but provide a clinically relevant starting point supporting preferential VMN use in acute practice.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101248"},"PeriodicalIF":1.8,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reporting of data on participant ethnicity and socioeconomic status in high impact respiratory journals: a targeted literature review 高影响力呼吸期刊中参与者种族和社会经济地位的数据报告：一项有针对性的文献综述

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2026-01-11 DOI: 10.1016/j.resmer.2026.101250

Ishani Kenny , Caitlin Meechan , Georgia Hopley , Rachel Snow , Arjun Menon , Diana David , Natasha Manuelpillai , Obada Katan , Keir E J Philip

Background

Demographic data, including ethnicity/race and socioeconomic status (SES), of research participants is required for interpretation and application of findings. The International Committee of Medical Journal Editors recommend inclusion of representative populations in studies, and to provide relevant demographic information, but they are not prescriptive in their recommendations. This study aimed to assess the reporting of ethnicity/race and SES in high-impact respiratory journals.

Method

The ten most recent research articles (to 18/10/24) from the top 10 respiratory journals (using h5-index), were selected and reviewed by two researchers independently. Data was collected on reporting of key demographic data, including age, sex/gender, ethnicity/race and SES.

Results

100 research articles were included. 43 contained demographic information on ethnicity/race, 10 on SES, 100 on age and 99 on sex/gender. Median reporting of ethnicity/race was 4/10 per journal (range 2–8), and only 5 studies acknowledged this as a limitation. The Lancet Respiratory Medicine, in which 8/10 articles contained ethnicity/race data and 1 of the remaining articles acknowledged the lack as a limitation, is the only journal to explicitly recommend inclusion of ethnicity/race or an explanation for lack of reporting. No journals recommended inclusion of SES data with globally poor reporting; a median of 1/10 articles per journal reported SES (range 0–2).

Conclusion

Reporting of ethnicity/race and SES in high impact respiratory journals is poor despite both being linked to health disparities. Explicit guidelines may improve reporting of key demographic data which would improve research interpretation and application.

研究背景需要研究参与者的人口统计数据，包括民族/种族和社会经济地位（SES），以解释和应用研究结果。国际医学杂志编辑委员会建议在研究中纳入有代表性的人群，并提供相关的人口统计信息，但他们的建议并没有规定。本研究旨在评估在高影响力的呼吸学期刊上关于种族/种族和社会经济地位的报道。方法选取国内外十大呼吸科学期刊（h5指数）中最近发表的10篇（至18/10/24）的研究论文，由2位研究者进行独立评审。数据收集于主要人口统计数据的报告，包括年龄、性别/性别、民族/种族和社会经济地位。结果共纳入100篇研究论文。43项载有族裔/种族的人口资料，10项载有社会经济地位资料，100项载有年龄资料，99项载有性别/性别资料。种族/种族报告的中位数为每份期刊4/10（范围2-8），只有5项研究承认这是一个局限性。《柳叶刀呼吸医学》是唯一明确建议纳入种族/种族或解释缺乏报告的期刊，其中8/10篇文章包含种族/种族数据，其余1篇文章承认缺乏种族/种族数据是一种限制。没有期刊建议纳入全球报告较差的SES数据；每本期刊报告SES的文章中位数为1/10（范围0-2）。结论：尽管民族/种族和社会经济地位与健康差异有关，但在高影响力呼吸期刊上的报道却很少。明确的指导方针可以改进关键人口数据的报告，从而改进研究的解释和应用。

{"title":"Reporting of data on participant ethnicity and socioeconomic status in high impact respiratory journals: a targeted literature review","authors":"Ishani Kenny , Caitlin Meechan , Georgia Hopley , Rachel Snow , Arjun Menon , Diana David , Natasha Manuelpillai , Obada Katan , Keir E J Philip","doi":"10.1016/j.resmer.2026.101250","DOIUrl":"10.1016/j.resmer.2026.101250","url":null,"abstract":"<div><h3>Background</h3><div>Demographic data, including ethnicity/race and socioeconomic status (SES), of research participants is required for interpretation and application of findings. The International Committee of Medical Journal Editors recommend inclusion of representative populations in studies, and to provide relevant demographic information, but they are not prescriptive in their recommendations. This study aimed to assess the reporting of ethnicity/race and SES in high-impact respiratory journals.</div></div><div><h3>Method</h3><div>The ten most recent research articles (to 18/10/24) from the top 10 respiratory journals (using h5-index), were selected and reviewed by two researchers independently. Data was collected on reporting of key demographic data, including age, sex/gender, ethnicity/race and SES.</div></div><div><h3>Results</h3><div>100 research articles were included. 43 contained demographic information on ethnicity/race, 10 on SES, 100 on age and 99 on sex/gender. Median reporting of ethnicity/race was 4/10 per journal (range 2–8), and only 5 studies acknowledged this as a limitation. The Lancet Respiratory Medicine, in which 8/10 articles contained ethnicity/race data and 1 of the remaining articles acknowledged the lack as a limitation, is the only journal to explicitly recommend inclusion of ethnicity/race or an explanation for lack of reporting. No journals recommended inclusion of SES data with globally poor reporting; a median of 1/10 articles per journal reported SES (range 0–2).</div></div><div><h3>Conclusion</h3><div>Reporting of ethnicity/race and SES in high impact respiratory journals is poor despite both being linked to health disparities. Explicit guidelines may improve reporting of key demographic data which would improve research interpretation and application.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101250"},"PeriodicalIF":1.8,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioactive peptides in therapeutic α1-Antitrypsin preparations modulate neutrophil chemokine receptors: Implications for augmentation therapy 治疗性α - 1抗胰蛋白酶制剂中的生物活性肽调节中性粒细胞趋化因子受体：增强治疗的意义

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2026-01-09 DOI: 10.1016/j.resmer.2026.101249

Julia Held , Jing Liu , Friedemann R. Börner , Michael Kiehntopf , Sabine Wrenger , Sabina Janciauskiene

引用次数: 0

Radiologist-reported tension features on x-ray are not associated with physiological instability in ED patients with primary spontaneous pneumothorax 放射科医生报告的x线张力特征与原发性自发性气胸ED患者的生理不稳定无关

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2026-01-09 DOI: 10.1016/j.resmer.2026.101247

Anne-Maree Kelly, Marsalina Heritrenggi, Matthew Birdsey, Samuel Peat

引用次数: 0

Frailty in COPD hospitalized patients: Associated factors from a multicentre cohort study COPD住院患者的虚弱：来自多中心队列研究的相关因素

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-12-15 DOI: 10.1016/j.resmer.2025.101239

Cristóbal Esteban , María Gascón , Eva Tabernero , Patricia Sobradillo , Monica Rayón , Ignacio García-Talavera , Amaia Aramburu , Leyre Chasco , José M. Quintana , the ReEPOC-REDISSEC group

Objective

The aim of the study was to determine the association between frailty and hospitalizations, mid-term mortality and medical readmissions, and to evaluate the relationship between frailty and other variables, such as dependence, anxiety, depression and health-related quality of life in a cohort of COPD patients after admission due to exacerbation (eCOPD).

Methods

Prospective observational cohort study conducted across nine Spanish hospitals. Patients were recruited consecutively. Variables relating to the patients' clinical baseline status were recorded, including the Tilburg Frailty Indicator (TFI), EuroQol EQ-5D, the COPD Assessment Test (CAT), Yale Physical Activity Survey (YPAS); the mMRC Dyspnea Scale, Hospital Anxiety and Depression Scale (HAD), and the Duke-UNC scale.

Results

1638 COPD patients were studied, with a mean age of 72.4 (SD 10.3), 77 % male, mean FEV1 49.4 % (SD 19.2), median Charlson index 2; mean CAT 21.3 (SD 9.1). In the multivariate analysis, the variables independently associated with frailty were older age, female sex, comorbidities, health-related quality of life, dyspnea, dependence, anxiety, depression, and physical activity. Multivariable survival regression analysis identified TFI, sex, and previous hospitalizations as predictors of one-year mortality. These variables, together with comorbidities, were associated with the risk of readmission due to any medical condition during the 1-year follow-up.

Conclusions

Frailty was associated with admission due to eCOPD and to the number of hospitalizations. In COPD, a single hospitalization should be considered a warning sign for frailty. Variables such as dependence, anxiety, depression and HRQoL were independent predictors of frailty. Additionally, frailty was associated with mortality and medical readmissions in the following year.

目的本研究的目的是确定虚弱与住院、中期死亡率和再入院之间的关系，并评估因急性加重（eCOPD）入院的COPD患者队列中虚弱与其他变量（如依赖、焦虑、抑郁和健康相关生活质量）之间的关系。方法在西班牙9家医院进行前瞻性观察队列研究。患者被连续招募。记录与患者临床基线状态相关的变量，包括Tilburg衰弱指标（TFI）、EuroQol EQ-5D、COPD评估测试（CAT）、Yale Physical Activity Survey (YPAS)；mMRC呼吸困难量表、医院焦虑抑郁量表（HAD）和Duke-UNC量表。结果共纳入COPD患者1638例，平均年龄72.4岁（SD 10.3），男性77%，平均FEV1 49.4% (SD 19.2)，中位Charlson指数2；平均CAT 21.3 （SD 9.1）。在多变量分析中，与虚弱独立相关的变量为年龄较大、女性、合并症、健康相关生活质量、呼吸困难、依赖性、焦虑、抑郁和体力活动。多变量生存回归分析确定TFI、性别和既往住院是一年死亡率的预测因子。在1年随访期间，这些变量以及合并症与任何医疗状况导致的再入院风险相关。结论慢性阻塞性肺病患者的虚弱程度与住院次数有关。在慢性阻塞性肺病中，一次住院治疗应被视为虚弱的警告信号。依赖性、焦虑、抑郁和HRQoL等变量是虚弱的独立预测因子。此外，虚弱与次年的死亡率和再入院率有关。

{"title":"Frailty in COPD hospitalized patients: Associated factors from a multicentre cohort study","authors":"Cristóbal Esteban , María Gascón , Eva Tabernero , Patricia Sobradillo , Monica Rayón , Ignacio García-Talavera , Amaia Aramburu , Leyre Chasco , José M. Quintana , the ReEPOC-REDISSEC group","doi":"10.1016/j.resmer.2025.101239","DOIUrl":"10.1016/j.resmer.2025.101239","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of the study was to determine the association between frailty and hospitalizations, mid-term mortality and medical readmissions, and to evaluate the relationship between frailty and other variables, such as dependence, anxiety, depression and health-related quality of life in a cohort of COPD patients after admission due to exacerbation (eCOPD).</div></div><div><h3>Methods</h3><div>Prospective observational cohort study conducted across nine Spanish hospitals. Patients were recruited consecutively. Variables relating to the patients' clinical baseline status were recorded, including the Tilburg Frailty Indicator (TFI), EuroQol EQ-5D, the COPD Assessment Test (CAT), Yale Physical Activity Survey (YPAS); the mMRC Dyspnea Scale, Hospital Anxiety and Depression Scale (HAD), and the Duke-UNC scale.</div></div><div><h3>Results</h3><div>1638 COPD patients were studied, with a mean age of 72.4 (SD 10.3), 77 % male, mean FEV1 49.4 % (SD 19.2), median Charlson index 2; mean CAT 21.3 (SD 9.1). In the multivariate analysis, the variables independently associated with frailty were older age, female sex, comorbidities, health-related quality of life, dyspnea, dependence, anxiety, depression, and physical activity. Multivariable survival regression analysis identified TFI, sex, and previous hospitalizations as predictors of one-year mortality. These variables, together with comorbidities, were associated with the risk of readmission due to any medical condition during the 1-year follow-up.</div></div><div><h3>Conclusions</h3><div>Frailty was associated with admission due to eCOPD and to the number of hospitalizations. In COPD, a single hospitalization should be considered a warning sign for frailty. Variables such as dependence, anxiety, depression and HRQoL were independent predictors of frailty. Additionally, frailty was associated with mortality and medical readmissions in the following year.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101239"},"PeriodicalIF":1.8,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An original story of a coma 一个关于昏迷的原创故事

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-12-12 DOI: 10.1016/j.resmer.2025.101241

Malo Miquel , Cécile Devloo , Alexandre Vasseur , Jéromine Alessandri , Jean-Philippe Rigaud , Pierre-Louis Declercq

引用次数: 0

Impact of having pulmonary embolism response team (PERT) on outcome of pulmonary embolism: A systematic review and meta-analysis 肺栓塞反应小组（PERT）对肺栓塞预后的影响：一项系统回顾和荟萃分析。

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-12-11 DOI: 10.1016/j.resmer.2025.101245

Sagun Dawadi , Dhan Bahadur Shrestha , Prakash Raj Oli , Raj Kumar Thapa , Jurgen Shtembari , Amit Bhandari , Daniel H. Katz

Introduction

Pulmonary embolism (PE) continues to pose a significant challenge in clinical practice. Selecting the optimal management approach is complicated by conflicting societal guidelines, which can hinder the care team's ability to deliver effective therapies in timely fashion. To address this complexity, the Pulmonary Embolism Response Team (PERT) was introduced in 2012. This study evaluates the effectiveness of PERT and explores its integration as a standard of care for PE management.

Methods

A systematic search of databases was conducted from inception to April 2024. Relevant references were identified and imported for analysis. Statistical evaluation was performed using RevMan Web, using odds ratios (OR) for dichotomous outcomes and mean differences (MD) for continuous outcomes.

Results

The analysis included 23 studies, comprising 15,621 patients in two groups: patient managed by PERT, n=5,555 and patient managed with standard treatment without PERT, n=10,066. The use of PERT significantly lowered odds of 30-day or in-hospital mortality (OR 0.76, CI 0.59-0.99) but significantly increased the utilization of advanced therapeutic strategies (OR 3.45, CI 1.95-6.09). Although PERT demonstrated favorable odds for reduced major bleeding events and earlier achievement of therapeutic anticoagulation but could not achive statistcal significance. Also, while PERT was associated with higher odds of ICU admission (OR 2.41, CI 1.33-4.34)but significantly reduced the length of ICU stay (MD -0.67, CI -1.28 to -0.05).

Conclusion

PERT implementation has been associated with reduced mortality, shorter ICU stays, at cost of higher utilization of advanced therapies. However, given that most studies are observational, these findings should be interpreted cautiously, and higher-quality research is needed to establish definitive benefit.

肺栓塞（PE）在临床实践中仍然是一个重大挑战。选择最佳的管理方法是复杂的矛盾的社会准则，这可能会阻碍护理团队的能力提供有效的治疗及时。为了解决这种复杂性，肺栓塞反应小组（PERT）于2012年成立。本研究评估了PERT的有效性，并探讨了其作为体育管理护理标准的整合。方法：系统检索自成立至2024年4月的数据库。识别并导入相关参考文献进行分析。使用RevMan Web进行统计评价，二分结果使用比值比（OR），连续结果使用平均差异（MD）。结果：该分析包括23项研究，包括15,621例患者，分为两组：采用PERT治疗的患者，n=5,555，以及采用不采用PERT治疗的标准治疗的患者，n=10,066。PERT的使用显著降低了30天或住院死亡率（or 0.76, CI 0.59-0.99），但显著增加了先进治疗策略的使用（or 3.45, CI 1.95-6.09）。虽然PERT在减少大出血事件和早期实现治疗性抗凝方面表现出有利的优势，但不能达到统计学意义。此外，虽然PERT与较高的ICU住院几率（OR 2.41, CI 1.33-4.34）相关，但显著缩短了ICU住院时间（MD -0.67, CI -1.28至-0.05）。结论：PERT的实施与降低死亡率，缩短ICU住院时间，以更高的先进治疗利用率为代价。然而，考虑到大多数研究是观察性的，这些发现应该谨慎解释，需要更高质量的研究来确定确切的益处。

{"title":"Impact of having pulmonary embolism response team (PERT) on outcome of pulmonary embolism: A systematic review and meta-analysis","authors":"Sagun Dawadi , Dhan Bahadur Shrestha , Prakash Raj Oli , Raj Kumar Thapa , Jurgen Shtembari , Amit Bhandari , Daniel H. Katz","doi":"10.1016/j.resmer.2025.101245","DOIUrl":"10.1016/j.resmer.2025.101245","url":null,"abstract":"<div><h3>Introduction</h3><div>Pulmonary embolism (PE) continues to pose a significant challenge in clinical practice. Selecting the optimal management approach is complicated by conflicting societal guidelines, which can hinder the care team's ability to deliver effective therapies in timely fashion. To address this complexity, the Pulmonary Embolism Response Team (PERT) was introduced in 2012. This study evaluates the effectiveness of PERT and explores its integration as a standard of care for PE management.</div></div><div><h3>Methods</h3><div>A systematic search of databases was conducted from inception to April 2024. Relevant references were identified and imported for analysis. Statistical evaluation was performed using RevMan Web, using odds ratios (OR) for dichotomous outcomes and mean differences (MD) for continuous outcomes.</div></div><div><h3>Results</h3><div>The analysis included 23 studies, comprising 15,621 patients in two groups: patient managed by PERT, n=5,555 and patient managed with standard treatment without PERT, n=10,066. The use of PERT significantly lowered odds of 30-day or in-hospital mortality (OR 0.76, CI 0.59-0.99) but significantly increased the utilization of advanced therapeutic strategies (OR 3.45, CI 1.95-6.09). Although PERT demonstrated favorable odds for reduced major bleeding events and earlier achievement of therapeutic anticoagulation but could not achive statistcal significance. Also, while PERT was associated with higher odds of ICU admission (OR 2.41, CI 1.33-4.34)but significantly reduced the length of ICU stay (MD -0.67, CI -1.28 to -0.05).</div></div><div><h3>Conclusion</h3><div>PERT implementation has been associated with reduced mortality, shorter ICU stays, at cost of higher utilization of advanced therapies. However, given that most studies are observational, these findings should be interpreted cautiously, and higher-quality research is needed to establish definitive benefit.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101245"},"PeriodicalIF":1.8,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Apical and basolateral alpha-1 antitrypsin delivery modulate CFTR and STAT3 in human airway epithelia grown at air-liquid interface 顶侧和底侧α -1抗胰蛋白酶递送调节气液界面培养的人气道上皮的CFTR和STAT3

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-12-10 DOI: 10.1016/j.resmer.2025.101236

Kokilavani Sivaraman , Stephanie Tamm , Elena Korenbaum , Beata Olejnicka , Wenzhang Si , Sabine Wrenger , Frauke Stanke , Sabina Janciauskiene

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Respiratory Medicine and Research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀